Generic Name and Formulations:
Glyburide 1.25mg, 2.5mg, 5mg; scored tabs.
Indications for DIABETA:
Adjunct to diet and exercise in type 2 diabetes mellitus.
Initially 2.5–5mg daily with breakfast or first main meal. Elderly or debilitated: initially 1.25mg daily. Increase by 2.5mg at weekly intervals if needed per blood glucose. Maintenance: 1.25–20mg daily in single or divided doses (consider divided doses above 10mg daily); max 20mg daily.
Type 1 diabetes or diabetic ketoacidosis with or without coma. Concomitant bosentan.
Oral hypoglycemic agents may increase risk of cardiovascular mortality. Renal or hepatic impairment. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, fasting blood glucose, and HbA1c levels periodically. Discontinue if jaundice or hepatitis occurs. Sulfonamide allergy. Malnourished. Elderly. Debilitated. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
Sulfonylurea (2nd generation).
See Contraindications. May be potentiated by NSAIDs, ACEIs, disopyramide, fluoxetine, clarithromycin, coumarin, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, MAOIs, β-blockers, oral miconazole (possibly), fluroquinolones. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid. Monitor closely for hypoglycemia with concomitant drugs that affect glucose metabolism and upon withdrawal. May increase cyclosporine levels; monitor and adjust cyclosporine dose. Caution with CYP2C9 inhibitors or inducers (eg, rifampin). May be antagonized by topiramate, colesevelam; administer glyburide ≥4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Hypoglycemia, nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias; rare: cholestatic jaundice, hepatitis.
Tabs 1.25mg—50; 2.5mg—100; 5mg—100, 1000
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib